PLK1 and atherosclerosis: Concurrently, ON-01910inhibits Polo-like kinase 1 (Plk1), engaging in the shared molecular mechanisms of cell proliferation and inflammation, thus paving a new route for the treatment of diabetes and atherosclerosis (33).